Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets open in green
Wed, 2 Sep 09:30 am

The major Asian stock markets have opened the day in green with stock markets in Japan, Singapore and China up 1.3%, 0.6% and 0.3% respectively, are leading the pack of gainers. The major stock indices in the European and US markets ended their previous session on a dismal note. The benchmark indices of US ended their previous session lower by 3.03%.The rupee is trading at 66.22 per US dollar.

Indian stock markets have opened the day on a flattish note. BSE-Sensex is trading up by 22 points (up 0.08%) and NSE-Nifty is trading up by 1.80 points (up 0.02%). S&P BSE Midcap is trading down by 0.2% and S&P BSE Smallcap is trading up by 0.3%. Sectoral indices have opened the day on a mixed note with stocks from oil and gas and automobile sector witnessing selling pressure. However stocks from telecommunication and tobacco sector are witnessing buying interest.

According to a financial daily, the foreign portfolio investors (FPIs) would be relieved from the payment of MAT from Minimum Alternative Tax (MAT) for the years prior to 1st April, 2015. The move is in line with the recommendations of the A.P. Shah committee. Reportedly, the government will introduce clarificatory amendments to the Income Tax (I-T) Act to exempt portfolio investors from MAT in the next session of parliament. The tax department will also issue a circular to its field formations to put on hold all existing demands as well as new demands. But uncertainty persists for 'foreign companies' because according to panel, relief will be provided only to 'FPIs' and not overseas corporate entity.

Major stocks in the pharmaceutical have opened their day in green. As per an articles in Business Standard, Sun Pharmaceutical has completed the acquisition of GlaxoSmithKline's (GSK's) opiates business in Australia. This would strengthen its Active Pharmaceutical Ingredients (API) and analgesic drug segments. The deal was announced in March, but the same was finalized yesterday. Under the deal, GSK's two manufacturing plant in Australia along with inventory will be transferred to Sun Pharma. US is the largest market for opiate-based medicines and the top-five pharmaceutical companies control over 60 per cent share in analgesic drugs made from controlled substances. The acquisition in Australia will thus help Sun Pharmaceuticals in improving its product sourcing and help grow analgesics business.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.